AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01207765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indium-111-ibritumomab tiuxetan
Description: 1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.
Study NCT01207765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y Zevalin
Description: Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
Study NCT01969240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest Pain Choice Decision Aid
Description: The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the emergency department visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
Study NCT05571241 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fast rehabilitation program
Description: 1-2 weeks (first post-op visit): Long thumb spica splint removed; Staples/stitches removed; Short hand-based thumb spica fitted for the patient Start Active Range of Motion Exercises (AROM) for thumb Add active assisted rang of motion exercises (AAROM) if no significant progress 6 weeks: Gradually wean off of splint during the day; wear for protection and/or more strenuous daily activities 6-8 weeks: Passive Range of Motion Exercises (PROM) (ie. stretching), if needed - (ie. No significant changes in ROM of thumb) 8-10 weeks: Resisted exercises/activities without splint on
Study NCT04436185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparisons of procedural pain
Description: This randomized experimental study with placebo and control groups
Study NCT02557698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneum oil bath
Study NCT00745147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal formula (CCH1)
Description: initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
Study NCT00745147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duphalac
Description: initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
Study NCT02040454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT02040454 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Therapy
Study NCT02040454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Study NCT02561650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COV155
Description: COV155 tablets
Study NCT01678352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Cohort 1 Cohort 2 Cohort 3
Study NCT01335841 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigation station coupled with a 3D fluoroscopy
Description: After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
Study NCT01335841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation station coupled with a 3D fluoroscopy
Description: After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
Study NCT01612650 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tomosynthesis
Description: 2 incidences 3D numeric mammography
Study NCT03707314 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Angiography with follow-on revascularisation if indicated
Description: Angiography with follow-on revascularisation (if indicated)
Study NCT00232817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (drug)
Description: nicotine nasal spray (3mg) before surgery
Study NCT01424267 — intervention group
Intervention type: DEVICE
Intervention: Zenith® Low Profile AAA Endovascular Graft
Description: Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
Study NCT03506828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical sympathectomy
Description: thoracoscopic sympathectomy
Study NCT03506828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation with phenol injection
Description: All patient in this group will have radiofrequency ablation of T2 and T3 sympathetic ganglia with phenol injection
Study NCT04225351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCAF+CM
Description: CAF procedure + collagen matrix
Study NCT04225351 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MCAT+CM
Description: Tunnel procedure + collagen matrix
Study NCT03657758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPA and rosuvastatin
Description: To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
Study NCT06124170 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative pain managment
Description: propaganda and education on pain; Preemptive analgesia with celecoxib (200 mg bid) 2 days before surgery
Study NCT01808573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT01808573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Study NCT04600258 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: The patients will receive 40g per day of dark chocolate for 2 months
Study NCT01148615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (AVE0005)
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT03657758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose rosuvastatin
Description: To take high dose rosuvastatin (10mg/day) for ９ months.
Study NCT02671591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-PrEP
Description: This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
Study NCT02671591 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control condition
Description: This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
Study NCT06124170 — intervention group
Intervention type: PROCEDURE
Intervention: Intraoperative pain managment
Description: Squeeze to expel blood (tourniquet); Before skin suture, 20 mL 0.5% ropivacaine was given subcutaneously for local infiltration anesthesia;
Study NCT06124170 — intervention group
Intervention type: PROCEDURE
Intervention: Postoperative pain managment
Description: The intravenous analgesia pump was placed until 48 h after surgery;On the second day after surgery, celecoxib (200 mg bid) was administered orally, and buprenorphine transdermal patch was applied externally until hospital discharge;FNB catheter was placed under the guidance of ultrasound and connected with an analgesic pump, the anesthesia lasted until 48 h after surgery ‡
Study NCT01584596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Dietary Guidelines
Description: This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).~The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist.
Study NCT01584596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Dietary Guidelines
Description: This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).~The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist.
Study NCT01584596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity Guidelines
Description: The physical activity education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. The adoption phase will be for 1 hour and 45 minutes for the first 4 weeks with classes occurring once per week in conjunction with the DG education classes. During the adoption phase, participants monitor their own walking using pedometers and attend weekly group meetings to review the previous week's walking behaviors, discuss preferred strategies for success, and set personally relevant and incremental steps/day goals. During the adherence phase (the remaining 8 weeks), participants will continue with their self-monitoring and goal-setting (using their pedometers), with reduced contact with the study interventionists over the telephone (biweekly).
Study NCT03153176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Training program 30 hours accumulated before, during and after intervention
Study NCT03153176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual level
Description: 7 to 10 minutes in Physical Education in class time, 3 sections for week during lunch break
Study NCT03153176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational level
Description: Inclusion of actions in the school curriculum: counseling sections with health for parents and adolescent, active lesson breaks during theoretical class, gardening experience in school, nutrition guidance for school lunch professionals.
Study NCT04609735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric Dry Needling, Manual Therapy, Exercise and Ultrasound
Description: Electric Dry Needling, Manual Therapy, Exercise and Ultrasound
Study NCT04609735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy, Exercise and Ultrasound
Description: Electric Dry Needling, Manual Therapy, Exercise and Ultrasound vs. Manual Therapy, Exercise and Ultrasound
Study NCT03102632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Water Intake
Description: After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.
Study NCT01232101 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: covered or uncovered stents
Description: Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.
Study NCT01860300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.
Study NCT01860300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01827982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 1mg
Description: JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
Study NCT01827982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 3 mg
Description: JNJ-54861911 3 mg will be administered as a single oral dose.
Study NCT03968588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus(reduced), Mycophenolate mofetil(standard)
Description: tacrolimus target trough blood level: 3\~8ng/mL MMF dose: 1.5\~2g/d
Study NCT03968588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus(standard), Mycophenolate mofetil(reduced)
Description: tacrolimus target trough blood level: 5\~15ng/mL MMF dose: 0.5\~1g/d
Study NCT01827982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 9 mg
Description: JNJ-54861911 9 mg will be administered as a single oral dose.
Study NCT01827982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 27 mg
Description: JNJ-54861911 27 mg will be administered as a single oral dose.
Study NCT01827982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 81 mg
Description: JNJ-54861911 81 mg will be administered as a single oral dose.
Study NCT01827982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 160 mg
Description: JNJ-54861911 160 mg will be administered as a single oral dose.
Study NCT01827982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 tbd
Description: The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
Study NCT01827982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 9 mg
Description: Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
Study NCT01827982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be given as a single oral dose.
Study NCT01612650 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D mammography
Description: 2 incidences 2D analogic mammography
Study NCT00927849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral internal sphincterotomy (LIS)
Description: closed lateral internal sphincterotomy was done under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
Study NCT00927849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin trinitrate (GTN)
Description: All were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
Study NCT00927849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin injection (BTX A)
Description: All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
Study NCT03536845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 3
Description: oral drops
Study NCT01148615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (XRP6976)
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT03074786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine
Description: Silicone elastomer vaginal matrix ring
Study NCT03074786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Tablets to be taken orally daily
Study NCT01722201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Tablet 1 mg
Description: 1 mg tablet once a day
Study NCT02961192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive social incentive
Description: A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
Study NCT02961192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive social incentive
Description: Participants in this intervention will be competing against each other in the game.
Study NCT02961192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative social incentive
Description: Participants in this intervention will be working with each other in the game.
Study NCT01688739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by subcutaneous injection or intravenous injection
Study NCT01688739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection or intravenous injection
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5442
Description: MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
Study NCT01321333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HuCNS-SC cells
Description: single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
Study NCT01070628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stalevo (levodopa/ carbidopa/ entacapone)
Description: 150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
Study NCT01070628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet (levodopa/carbidopa)
Description: 150 or 100 mg levodopa q.i.d. in 3.5 hr interval
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-5442
Description: Matching placebo to MK-5442 taken orally, once-daily, for 12 months
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-5442
Description: Matching placebo to MK-5442 taken orally, once-daily, for 12 months
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate Sodium
Description: Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
Study NCT00996801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
Study NCT01149161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine central neck dissection
Description: Level VI neck node dissection during thyroid operation
Study NCT01050140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high sugar diet
Description: 25% of dietary energy from fructose or glucose
Study NCT01050140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high sugar diet
Description: 25% of dietary energy from fructose or glucose
Study NCT04102657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.
Study NCT04102657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free-Living Diet
Description: Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.